Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares)
-
Shares outstanding
-
239,647,920
-
Total 13F shares
-
40,542,745
-
Share change
-
+3,582,387
-
Total reported value
-
$4,273,885,983
-
Put/Call ratio
-
108%
-
Price per share
-
$105.54
-
Number of holders
-
277
-
Value change
-
+$369,420,974
-
Number of buys
-
150
-
Number of sells
-
106
Institutional Holders of BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) as of Q4 2023
As of 31 Dec 2023,
BioNTech SE - Ordinary Shares, no par value per share (EUR1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (BNTX) was held by
277 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,542,745 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, PRIMECAP MANAGEMENT CO/CA/, Temasek Holdings (Private) Ltd, HARDING LOEVNER LP, FLOSSBACH VON STORCH AG, BlackRock Inc., UBS ASSET MANAGEMENT AMERICAS INC, Capital World Investors, ALTRINSIC GLOBAL ADVISORS LLC, and Quinn Opportunity Partners LLC.
This page lists
278
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.